Novo Nordisk (NVO) had another tough session yesterday, finishing more than 2% lower compared to Friday’s close. The pharmaceutical company behind well-known drugs like Wegovy and Ozempic has struggled throughout the year, and the stock now sits more than 50% below its highs from earlier in 2024.